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Abstract
Background
Obesity increases the risk for developing gestational diabetes mellitus (GDM) and pre-
eclampsia (PE), which both associate with increased risk for type 2 diabetes mellitus
(T2DM) and cardiovascular disease (CVD) in women in later life. In the general population,
metabolic syndrome (MetS) associates with T2DM and CVD. The impact of maternal MetS
on pregnancy outcomes, in nulliparous pregnant women, has not been investigated.
Methods and findings
Low-risk, nulliparous women were recruited to the multi-centre, international prospective
Screening for Pregnancy Endpoints (SCOPE) cohort between 11 November 2004 and 28
February 2011. Women were assessed for a range of demographic, lifestyle, and metabolic
health variables at 15 ± 1 weeks’ gestation. MetS was defined according to International Dia-
betes Federation (IDF) criteria for adults: waist circumference�80 cm, along with any 2 of
the following: raised trigycerides (�1.70 mmol/l [�150 mg/dl]), reduced high-density lipopro-
tein cholesterol (<1.29 mmol/l [<50 mg/dl]), raised blood pressure (BP) (i.e., systolic BP
�130 mm Hg or diastolic BP�85 mm Hg), or raised plasma glucose (�5.6 mmol/l). Log-
binomial regression analyses were used to examine the risk for each pregnancy outcome
(GDM, PE, large for gestational age [LGA], small for gestational age [SGA], and spontane-
ous preterm birth [sPTB]) with each of the 5 individual components for MetS and as a com-
posite measure (i.e., MetS, as defined by the IDF). The relative risks, adjusted for maternal
BMI, age, study centre, ethnicity, socioeconomic index, physical activity, smoking status,
depression status, and fetal sex, are reported. A total of 5,530 women were included, and
12.3% (n = 684) had MetS. Women with MetS were at an increased risk for PE by a factor of
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1.63 (95% CI 1.23 to 2.15) and for GDM by 3.71 (95% CI 2.42 to 5.67). In absolute terms, for
PE, women with MetS had an adjusted excess risk of 2.52% (95% CI 1.51% to 4.11%) and,
for GDM, had an adjusted excess risk of 8.66% (95% CI 5.38% to 13.94%). Diagnosis of
MetS was not associated with increased risk for LGA, SGA, or sPTB. Increasing BMI in
combination with MetS increased the estimated probability for GDM and decreased the
probability of an uncomplicated pregnancy. Limitations of this study are that there are sev-
eral different definitions for MetS in the adult population, and as there are none for preg-
nancy, we cannot be sure that the IDF criteria are the most appropriate definition for
pregnancy. Furthermore, MetS was assessed in the first trimester and may not reflect pre-
pregnancy metabolic health status.
Conclusions
We did not compare the impact of individual metabolic components with that of MetS as a
composite, and therefore cannot conclude that MetS is better at identifying women at risk.
However, more than half of the women who had MetS in early pregnancy developed a preg-
nancy complication compared with just over a third of women who did not have MetS. Fur-
thermore, while increasing BMI increases the probability of GDM, the addition of MetS
exacerbates this probability. Further studies are required to determine if individual MetS
components act synergistically or independently.
Author summary
Why was this study done?
• Obesity increases the risk for developing gestational diabetes mellitus (GDM) and pre-
eclampsia (PE), which both associate with increased risk for type 2 diabetes mellitus
(T2DM) and cardiovascular disease (CVD) in women in later life.
• In the general population, metabolic syndrome (MetS) associates with T2DM and CVD.
• The impact of maternal MetS on pregnancy outcomes in nulliparous pregnant women
has not been thoroughly investigated.
What did the researchers do and find?
• We assessed the association between MetS, measured at 15 ± 1 weeks’ gestation, and a
range of pregnancy complications in low-risk, nulliparous women recruited to the
multi-centre, international prospective Screening for Pregnancy Endpoints (SCOPE)
study.
• Women with MetS in early pregnancy had an increased risk for GDM and PE, after
adjustment for a range of demographic and lifestyle variables.
What do these findings mean?
• Diagnosis of MetS may be useful to broadly identify a group of women at risk for preg-
nancy complications, which may additionally associate with future CVD risk.
Metabolic syndrome and pregnancy complications
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• Future studies are required to substantiate our findings and to determine whether MetS
is a useful discriminator of pregnancy complications in lean and obese women. Future
studies are also encouraged to define clear metabolic health phenotypes that will pro-
duce the optimal probability threshold for each outcome.
Introduction
Obesity is an established risk factor for pregnancy complications, increasing risk for gesta-
tional diabetes mellitus (GDM), preeclampsia (PE), and delivering large for gestational age
(LGA) infants, by 2- to 3-fold [1–4], and small for gestational age (SGA) infants, by 24% [5].
Such adverse outcomes place women and their infants at greater risk for cardiovascular and
metabolic diseases both perinatally and in later life [6,7]. However, not all obese women expe-
rience a pregnancy complication [8], nor do they all develop chronic disease [9].
Metabolic syndrome (MetS) is a cluster of risk factors that encompasses metabolic, vascular,
and inflammatory indicators. Although there are several definitions and cut-points used to
describe and characterise MetS [10], the metabolic disturbances underpinning MetS are con-
sistent and include atherogenic dyslipidemia, raised blood pressure (BP), insulin resistance,
obesity, and pro-thrombotic and pro-inflammatory states. While some expert definitions
deem obesity an essential criterion [11,12], other definitions largely focus on insulin resistance
[11,13,14]. To date, there are no obligatory components to define MetS [11] but rather a con-
stellation of risk factors that, irrespective of components and cut-offs, have consistently been
demonstrated to increase risk for cardiovascular disease (CVD) [15], some cancers [16], type 2
diabetes mellitus (T2DM) [17], and chronic kidney disease [18] in the adult population.
Normal pregnancy is a pro-inflammatory, pro-thrombotic, highly insulin resistant [19],
and hyperlipidemic state [20]. However, there are no recognised healthy metabolic variable
cut-points in pregnancy. Studies that have assessed metabolic components in pregnancy have
generally used accepted definitions for the adult population [21,22] or used a range of popula-
tion-specific criteria [23–25]. Appropriate definitions that associate metabolic health parame-
ters and pregnancy complications have yet to be defined, and the utility of using previously
defined variables from the non-pregnant adult population is unclear.
Given the established links between MetS and chronic diseases in adulthood [15,17], as well
as between pregnancy complications such as PE and GDM and later life T2DM and CVD
[26,27], pregnancy may offer a window of opportunity to identify women with MetS and ele-
vated risk of adverse pregnancy outcomes, as well as later life chronic disease. Most studies to
date, however, have only assessed individual metabolic components in pregnancy: raised tri-
glycerides (TGs) and low-density lipoprotein cholesterol (LDL-C) and reduced high-density
lipoprotein cholesterol (HDL-C) are associated with increased risk for GDM, PE, LGA, and
spontaneous preterm birth (sPTB) [24,25,28]. In a small study, multiparous Greek women
who had MetS, determined in early pregnancy, were at a 3-fold increased risk for preterm
birth [29].
Assessment of MetS and a broader range of pregnancy complications in nulliparous
women has not been done. We hypothesized that women with MetS are at greater risk for
pregnancy complications than women who do not have MetS. The aims of this study were to
(i) determine the prevalence of MetS in women participating in the Screening for Pregnancy
Endpoints (SCOPE) study and (ii) determine whether MetS is associated with maternal and
neonatal outcomes including GDM, LGA, PE, SGA, and sPTB.
Metabolic syndrome and pregnancy complications
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Methods
Study population
Participants recruited to SCOPE were nulliparous pregnant women recruited from Adelaide
(Australia), Auckland (New Zealand), Cork (Ireland), Leeds (UK), London (UK), and Man-
chester (UK) (n = 5,628). SCOPE is a multi-centre prospective cohort study with the primary
aim of developing screening tests for prediction of PE, sPTB, and SGA babies. Recruitment
was between 11 November 2004 and 28 February 2011, and data collection occurred until 30
September 2011, when the last babies were born. Included women were nulliparous with sin-
gleton pregnancies. Women were excluded if they were considered to be at high risk for PE,
SGA, or sPTB due to underlying medical conditions (e.g., chronic hypertension requiring anti-
hypertensive medication or diabetes); if they had previous cervical knife cone biopsy; if they
had 3 terminations or 3 miscarriages; if their pregnancy was complicated by a known major
fetal anomaly or abnormal karyotype; or if they received interventions that may modify preg-
nancy outcome (e.g., aspirin or cervical suture). Women were also excluded if they were taking
supplements of calcium (>1 g/d), eicosopentanoic acid (�2.7 g/d), vitamin C (>1,000 mg/d),
or vitamin E (>400 IU/d) or if they had diabetes (type 1 or type 2). An uncomplicated preg-
nancy was defined as a normotensive pregnancy, delivered at�37 weeks, resulting in a live-
born, non-SGA, and non-LGA baby. Pregnancies with other complications—such as placenta
praevia, placental abruption, cholestasis of pregnancy, or other significant pregnancy compli-
cation—were not included in the uncomplicated pregnancy group.
Study data were obtained by a research midwife at 15 ± 1 weeks’ gestation, including demo-
graphics; smoking; family, medical, and gynaecological history; diet and supplement use; sys-
tolic and diastolic BP; height and weight (measured at 15 ± 1 weeks’ gestation, to determine
BMI), and waist circumference (WC). The socioeconomic index (SEI) is a measure of the indi-
vidual’s socioeconomic status and is derived from the specific occupation of the woman, pro-
ducing a score between 10 and 90, with a lower score reflecting greater disadvantage [30]. The
Edinburgh Postnatal Depression Scale was evaluated at 15 weeks’ gestation, and women were
categorised as unlikely to experience depression (score <5), at increased risk of depression in
the next year (score of 5–9), or likely depressed (score >9). Physical activity at 15 weeks’ gesta-
tion was categorised as none (no moderate or vigorous exercise, with�1 instance/day of recre-
ational walking), light (no moderate or vigorous exercise, with >1 instance/day of recreational
walking), or moderate or vigorous (some moderate or vigorous exercise, with or without recre-
ational walking). Ethnicity was binary, coded as white or other. Smoking status was binary,
coded as yes or no for any cigarette smoking at 15 ± 1 weeks’ gestation.
A non-fasting blood sample was taken for measurement of HDL-C and TGs at 15 ± 1
weeks’ gestation. Details of the immunoassay methodology for measuring lipids can be found
in previous publications [31,32]. Plasma blood glucose was measured as a random blood sam-
ple by glucometer at 15 ± 1 weeks’ gestation. Additional information on data collection has
been provided in detail previously [33]. Ethical approval was obtained from local ethics com-
mittees (New Zealand AKX/02/00/364; Australia REC 1712/5/2008; London, Leeds, and Man-
chester 06/MRE01/98; and Cork ECM5 [10] 05/02/08), and all women provided written
informed consent. The study is reported as per STROBE guidelines (S1 STROBE Checklist).
Maternal exposure: MetS
We defined MetS using the International Diabetes Federation (IDF) MetS criteria [12],
assessed at 15 ± 1 weeks’ gestation. A WC�80 cm is a prerequisite risk factor, along with any
2 of the 4 following variables: raised TGs (�1.70 mmol/l [�150 mg/dl]), reduced HDL-C
Metabolic syndrome and pregnancy complications
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(<1.29 mmol/l [<50 mg/dl]), raised BP (i.e., systolic BP�130 mm Hg or diastolic BP�85
mm Hg), or raised fasting plasma glucose (�5.6 mmol/l). As this was a pregnancy cohort, a
random plasma glucose was measured. The utility of random plasma glucose has recently been
demonstrated in a sample of 25,543 women in the UK, showing that in 69% of these women,
random plasma glucose was able to predict GDM (area under the curve [AUC] 0.8) better
than maternal BMI (AUC 0.65) and maternal age (AUC 0.60) [34].
Primary outcome measures: Pregnancy and birth outcomes
PE was defined as systolic BP�140 mm Hg or diastolic BP�90 mm Hg, or both, on at least 2
occasions at least 4 hours apart after 20 weeks’ gestation but before the onset of labour, or post-
partum, with either proteinuria (24-hour urinary protein�300 mg or spot urine protein:creat-
inine ratio�30 mg/mmol creatinine or urine dipstick protein� ++) or any multisystem
complication of PE [33,35]. GDM was defined using the new World Health Organization clas-
sification (fasting glucose of�5.1 mmol/l or, following an oral glucose tolerance test, a 2-hour
level of�8.5 mmol/l) [36]. Universal screening was not employed for GDM in Ireland and the
UK; women were only screened if they were identified as being at risk based on factors such as
family history and BMI. Therefore, GDM analysis was confined only to women from Australia
and New Zealand (n = 3,126). sPTB was defined as spontaneous delivery before 37 + 0 weeks’
gestation. Infant measurements (head circumference, length, and birth weight) were recorded
by research midwives within 72 hours of birth. Customised birth weight centiles were calcu-
lated correcting for gestational age at birth, maternal ethnicity, maternal weight and height in
early pregnancy, parity, and infant sex [37]. SGA and LGA were defined as a birth weight
<10th or >90th customised centile, respectively.
Statistical analyses
Missing data. For the 5,628 eligible women for whom follow-up data were available, the
proportion of missing data for the metabolic variables and the covariates was <2% (S1 Table),
such that 97.5% of the data were included in the complete case analysis.
Main analyses. Log-binomial regression analyses were used to examine the risk for each
pregnancy outcome (GDM, LGA, PE, SGA, and sPTB) with each of the 5 individual components
for MetS and as a composite measure. The relative risks, adjusted for maternal BMI, age, study
centre (Adelaide, Auckland, Cork, Leeds, London, or Manchester), ethnicity, SEI, physical activ-
ity, smoking status, depression status, and fetal sex, are reported. The corresponding 95% CIs for
MetS and its components were calculated defined by pd[(RR − 1)/RR] [38], where pd is the pro-
portion of cases with MetS and RR is the adjusted relative risk. Generalised additive models
(GAMs) [39], using the GAMLSS R package, were used to examine the risk for each pregnancy
outcome by MetS status, with a non-linear penalised spline for BMI and an interaction term
between BMI and MetS status, adjusting for potential confounders identified a priori. The statisti-
cal software used was R version 3.4.3. The alpha level of significance was set at 5% (i.e., P<0.05).
Supplementary analyses. Box plots demonstrating median (interquartile range) for each
metabolic abnormality, split by MetS status, were drawn, and frequencies (n, percent) of
women with each pregnancy complication and with each metabolic abnormality were
described. To identify the frequency for each combination of MetS components, with and
without stratification for BMI, UpSet plots were used to show the overall frequency of each cri-
terion (left bar chart in S3–S5 Figs) and all observed combinations (indicated by dots at the
bottom of the figures), sorted from highest to lowest frequency.
Analysis formulation. A detailed analysis plan was not written prior to the initiation of
the project. However, based on the objectives of this study, we defined all basic analyses to be
Metabolic syndrome and pregnancy complications
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undertaken in a written document approved by the SCOPE Consortium Scientific Committee
(S1 Text), as well as in meetings with all primary authors, including epidemiologists, clinicians,
and statisticians, before the start of the analyses. Confounders were identified a priori through
the use of directed acyclic graphs. Changes in the analysis plan are described in S1 Text.
Results
Descriptive characteristics
A total of 5,530 women were included in the current analysis. S1 Fig shows the participant
flow. Overall, 12.3% (n = 684) had MetS. Table 1 describes maternal and infant characteristics
according to whether women did or did not have MetS. Women with MetS had an approxi-
mately 5-kg/m2 higher average BMI, had a lower average SEI, and were more likely to smoke,
and the mean gestational age at birth was slightly lower.
Metabolic health characteristics
Box plots of measured values for each metabolic component in women with and without MetS
are shown in S2 Fig. S2 Table shows the number and percentage of women with each meta-
bolic abnormality, in women with and without MetS. In women with MetS, 88.3% of women
had TGs above the IDF MetS cut-point, and 83.9% had raised glucose. All women, by defini-
tion, had a high WC. In comparison, in women who did not have MetS, 55.2% had high WC,
28.4% had raised glucose, and 20.8% had raised TGs.
S3 Fig shows the UpSet plot with the frequency for each combination of MetS components,
and S4 Fig and S5 Fig show the UpSet plots for women with BMI <30 kg/m2 and�30 kg/m2,
respectively. WC�80 cm was the most common single criterion, followed by the combination
of WC and glucose. S3 Table shows the number and percentage of women with each preg-
nancy complication according to MetS.
MetS and pregnancy outcomes
For each pregnancy complication, the relative risk, the number of women with MetS or its
individual components (N), and the number of women with the outcome (n) are shown in Fig
1. Individual MetS components that increased risk for PE were raised BP (RR 1.73, 95% CI
1.11 to 2.68), raised TGs (RR 1.73, 95% CI 1.37 to 2.18), and high WC (1.43, 95% CI 1.04 to
1.96), after adjusting for maternal BMI, age, study centre, ethnicity, SEI, physical activity,
smoking status, depression status, and fetal sex. Of the total cohort, the number of women
with raised BP at 15 weeks’ gestation was small (n = 158); 20 (12.7%) of these women devel-
oped PE. In all, 3,346 women had a high WC, and 213 (6.4%) developed PE. Raised glucose
and reduced HDL-C were not significantly associated with risk for PE. Women with MetS
were at an increased risk for PE, with a relative risk of 1.63 (95% CI 1.23 to 2.15), and 66
(9.7%) of these women developed PE. In absolute terms, women with MetS had an adjusted
excess risk of 2.52% (95% CI 1.51% to 4.11%), with a number needed to harm of 40.
Individual MetS components that increased risk for GDM were raised TGs (RR 3.38, 95% CI
2.24 to 5.10), raised BP (RR 2.69, 95% CI 1.43 to 5.05), and raised glucose (RR 2.46, 95% CI 1.63
to 3.72) (Fig 1). Ninety-eight women had raised BP, of whom 12 (12.2%) developed GDM; 796
women had raised TGs, of whom 65 (8.2%) developed GDM; and 1,091 women had raised glu-
cose, of whom 67 (6.1%) developed GDM. High WC and reduced HDL-C were not associated
with risk for GDM. Women with MetS were at the greatest increased risk for GDM, with a rela-
tive risk of 3.71 (95% CI 2.42 to 5.67). In absolute terms, women with MetS had an adjusted
excess risk of 8.66% (95% CI 5.38% to 13.94%), with a number needed to harm of 12.
Metabolic syndrome and pregnancy complications
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Risk for SGA was increased with raised BP (RR 1.89, 95% CI 1.33 to 2.68), but not with any
of the other metabolic components, nor with MetS. For sPTB, risk was increased with raised
TGs (RR 1.35, 95% CI 1.02 to 1.77), but not with any of the other metabolic components, nor
Table 1. Maternal and infant characteristics according to maternal metabolic syndrome, at 15 weeks’ gestation.
Characteristic Metabolic syndrome P value
No
(n = 4,846)
Yes
(n = 684)
Age, years 28.6 ± 5.4 28.8 ± 5.9 0.5453
Body mass index, kg/m2 24.7 ± 4.5 29.5 ± 5.7 0.0000
Socioeconomic index 42.1 ± 16.6 39.4 ± 15.7 0.0001
Ethnicity
White 4,361 (90.0%) 618 (90.4%) Ref
Other 485 (10.0%) 66 (9.7%) 0.8217
Study centre (country)
Adelaide (Australia) 952 (19.6%) 201 (29.4%) Ref
Cork (Ireland) 1,572 (32.4%) 192 (28.1%) 0.0000
Auckland (New Zealand) 1,740 (35.9%) 237 (34.6%) 0.0001
Leeds (UK) 132 (2.7%) 12 (1.8%) 0.0391
London (UK) 173 (3.6%) 6 (0.9%) 0.0000
Manchester (UK) 277 (5.7%) 36 (5.3%) 0.0732
Physical activity
None 766 (15.9%) 116 (17.0%) Ref
Light 317 (6.6%) 40 (5.9%) 0.8004
Moderate or vigorous 3,741 (77.5%) 526 (77.1%) 1.0000
Smoked at 15 weeks’ gestation 495 (10.2%) 101 (14.8%) 0.0004
Depression category
Unlikely to be depressed 1,784 (37.0%) 252 (36.9%) Ref
Increased risk of depression 1,783 (37.0%) 234 (34.3%) 0.9531
Likely to be depressed 1,257 (26.0%) 197 (28.8%) 0.6662
Fetal sex
Male 2,468 (51.1%) 338 (49.6%) Ref
Female 2,364 (48.9%) 343 (50.4%) 0.5064
Gestational age at birth, weeks 39.6 ± 2.5 39.3 ± 2.8 0.0027
Birth weight, g 3,402.0 ± 576.5 3,405.1 ± 673.5 0.3839
Birth weight centile 47.8 ± 28.9 46.5 ± 30.5 0.2156
Birth length, cm 50.3 ± 3.1 50.1 ± 3.4 0.4818
Head circumference, cm 34.6 ± 1.9 34.7 ± 2.2 0.0986
Delivered post-term
No (�41 weeks) 3,804 (78.5%) 546 (79.8%) Ref
Yes (>41 weeks) 1,042 (21.5%) 138 (20.2%) 0.4575
Ponderal index
Male 2.67 ± 0.41 2.67 ± 0.29 0.7445
Female 2.70 ± 0.34 2.71 ± 0.30 0.5101
Categorical variables are presented as number (percentage), and continuous variables as mean ± standard deviation. All variables (except fetal sex and birth outcomes)
were collected at 15 ± 1 weeks’ gestation. P value is compared to reference group. The socioeconomic index is a measure of the individual’s socioeconomic status and is
derived from the specific occupation of the woman, producing a score between 10 and 90 [30]. Depression status was evaluated using the Edinburgh Postnatal
Depression Scale. Customised birth weight centiles were calculated correcting for gestational age at birth, maternal ethnicity, maternal weight and height in early
pregnancy, parity, and infant sex [37].
https://doi.org/10.1371/journal.pmed.1002710.t001
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with MetS. Raised glucose modestly increased risk for LGA (RR 1.23, 95% CI 1.04 to 1.45), but
none of the other individual metabolic components, nor MetS, increased risk for LGA. MetS
was associated with reduced probability of having an uncomplicated pregnancy (RR 0.82, 95%
CI 0.73 to 0.93). In absolute terms, for having any pregnancy complication, women with MetS
had an adjusted excess risk of 9.35% (95% CI 10.30% to 7.98%), with a number needed to
harm of 11. Obesity (BMI�30 kg/m2) increased risk for GDM (RR 3.28, 95% CI 2.22 to 4.84),
PE (RR 1.91, 95% CI 1.47 to 2.47), and SGA (RR 1.27, 95% CI 1.04 to 1.56).
Fig 1. Forest plots for each pregnancy complication, the relative risk, the number of women with MetS or its individual components (N), and the number of
women with the outcome (n). All models (except BMI on the forest plot, which represents BMI<30 kg/m2 as the reference compared to BMI�30 kg/m2) were
adjusted for maternal BMI, age, study centre, ethnicity, socioeconomic index, physical activity, smoking status, depression status, and fetal sex. N = number of
women with the metabolic abnormality; n = number of cases (i.e., women who had the outcome). HDL-C, high-density lipoprotein cholesterol; MetS, metabolic
syndrome; RR, relative risk.
https://doi.org/10.1371/journal.pmed.1002710.g001
Metabolic syndrome and pregnancy complications
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002710 December 4, 2018 8 / 16
To determine the adjusted probability of pregnancy complications with increasing maternal
BMI (non-linear) according to MetS, we used penalised spline (cubic spline with 4 knots) anal-
ysis in GAMs (Fig 2). As maternal BMI increases, the presence of MetS increases the estimated
probability for GDM and SGA and also decreases the probability of an uncomplicated
pregnancy.
Discussion
Main findings
To our knowledge, this is the first large, population-based, multi-centre prospective cohort
study in low-risk nulliparous pregnant women to assess the association between MetS—rather
than just its individual components—at 15 weeks’ gestation and pregnancy outcomes. We
report that 12.3% (n = 684) of women had MetS, and these women were at an increased risk
for PE and GDM, after adjustment for a range of demographic and lifestyle variables. Increas-
ing BMI in combination with MetS also increased the estimated probability for GDM, and
decreased the probability of an uncomplicated pregnancy. The findings build on the literature
assessing the effects of individual metabolic health components or obesity on pregnancy com-
plications, by using established clustering of abnormalities that are evident in non-obese preg-
nant women.
Comparison to literature
There is an abundance of literature demonstrating that maternal obesity increases risk for
pregnancy complications including GDM and PE [40–42] and also for babies born too small
or large [43]. Some studies reporting on individual metabolic components, such as raised TGs
or LDL-C or reduced HDL-C, and pregnancy complications show that these are associated
with increased risk for GDM, PE, LGA, and sPTB [28]. In addition, raised maternal glucose,
insulin resistance, and raised BP are associated with GDM [44,45], and pre-pregnancy WC is
associated with GDM and LGA [46]. Examination of a composite of components (MetS) and
its association with pregnancy complications extends these earlier studies assessing individual
components.
Currently, all obese pregnant women are considered to be at the same increased risk for
GDM. However, only 15%–30% of these women will develop the disorder [47]. Recently, in a
sample of 1,303 obese pregnant women, a model based on clinical and anthropometric vari-
ables (e.g., age and systolic BP) could modestly predict GDM (AUC 0.71), with the AUC
increased to 0.77 with the addition of candidate biomarkers such as random glucose and TGs
[48]. However, while obese women are at higher risk for GDM than their lean or overweight
counterparts, 7%–15% of lean women may still develop GDM [49,50]. Our results suggest that
assessment of MetS in all pregnant women may provide information on risk for GDM that
extends beyond BMI. Although MetS conferred a slightly greater risk for GDM than glucose,
TGs, and WC assessed individually, the impact of MetS as a function of a combination of com-
ponents or exclusion of certain components requires investigation in other pregnancy cohorts.
Additionally, whether MetS improves prediction of risk of GDM above that of raised glucose
alone needs to be examined, and should be assessed in women who are obese or not. This will
help determine any applicability of diagnosing MetS in the antenatal setting, in addition to
standard BMI and glucose measurements.
Recent figures estimate that PE affects 2%–7% of pregnancies and occurs more frequently
in nulliparous women [51]. Women who have experienced PE are at a more than 2-fold
increased risk for future CVDs such as hypertension and ischemic heart disease [52]. Early
identification of women at risk for PE remains one of the major focuses of antenatal care. We
Metabolic syndrome and pregnancy complications
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Fig 2. Predicted probability of each pregnancy outcome for women who did and did not have MetS and the interaction with BMI, estimated from the
generalised additive model. Models adjusted for maternal BMI (as a spline), age, study centre, ethnicity, socioeconomic index, physical activity, smoking status,
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found that MetS, a risk factor for future CVD, increased the risk for PE, but in combination
with increasing BMI did not demonstrate greater risk. We found that a smaller number of
women had raised BP (n = 198) than had MetS (n = 681), but a similar proportion of each
went on to develop PE (~10%). Future work comparing whether MetS provides risk informa-
tion beyond that of raised BP would be useful.
Health implications and clinical relevance
Traditionally, antenatal care pathways are based on individual needs, history, and specific risk
factors such as obesity. Despite the best care, a number of women still go on to develop preg-
nancy complications. Not all available screening tests are offered to all women, and some are
only offered to those who are deemed at risk. Testing for impaired glucose tolerance in early
pregnancy is rarely provided but may be undertaken before 24 weeks’ gestation if the woman
has risk factors. Some guidelines recommend that women have their risk for GDM evaluated
by assessment of maternal risk factors followed by an oral glucose tolerance test when
required. Furthermore, in nulliparous women, risk assessment for other pregnancy complica-
tions such as PE is difficult as there is no maternal history and no widely adopted screening
test.
Our findings suggest that MetS diagnosed in early pregnancy may be used to broadly iden-
tify women at increased risk for pregnancy complications. The utility of MetS in predicting
pregnancy complications, as a complementary component to standard routine antenatal care
and compared to standard risk factors, requires exploration. Future studies are also encour-
aged to define clear metabolic health phenotypes that will produce the optimal probability
threshold for each outcome.
Strengths and limitations
The major strength of this study is that it used a population-based prospective cohort design
that included a large number of nulliparous women across 6 centres in 4 countries. Partici-
pants comprised a clearly defined population of nulliparous low-risk women with no pre-exist-
ing disease, which should be considered in study design for other populations. Risk estimates
may potentially be underestimated for the general population as the participants in this study
are at low risk for pregnancy complications compared to the general population of pregnant
women. The study captured 5,530 pregnant women for whom complete information on
plasma and other maternal metabolic variables and pregnancy and neonatal outcomes was
available. These were ascertained using rigorous assessment methods standardised across
recruiting centres, resulting in negligible information bias. A key strength is the assessment of
individual and composite MetS compoments and pregnancy complications, which have not
been thoroughly investigated to date.
There are limitations in this study. Currently, there are several different definitions for
MetS in the adult population as different numbers and types of metabolic variables are used, as
well as different cut-off values, between studies [10,11]. However, there are no definitions at all
specifically for pregnancy, and, despite pregnancy being a hyperlipidemic state, there is no
agreed threshold for pathological hyperlipidemia in pregnancy. We used the IDF definition
for MetS for adults, as previous studies have demonstrated no remarkable increase in lipids in
first trimester of pregnancy [53], and it is unlikely that WC would have significantly increased
depression status, and fetal sex, with an interaction term between the metabolic groups and BMI. GDM, gestational diabetes mellitus; LGA, large for gestational age;
MetS, metabolic syndrome; PE, preeclampsia; SGA, small for gestational age; sPTB, spontaneous preterm birth.
https://doi.org/10.1371/journal.pmed.1002710.g002
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at the time of recruitment at 15 weeks’ gestation. There may be inherent limitations with using
non-fasting compared to fasting metabolic components, particularly for TGs and glucose;
however, an increased risk for PE and GDM has been demonstrated using fasting [25,54,55]
and non-fasting [56–61] lipids. Universal screening for GDM in the UK and Ireland was not
available at the time of recruitment, and screening was only undertaken for women who were
deemed at risk; thus, we only included data for the centres with universal screening (n = 3126)
for this outcome. A recent study has highlighted the importance of early screening for GDM
in obese women, demonstrating differences in metabolic profile between obese women who
do and do not develop GDM [45]. Finally, assessment of MetS was made in the first trimester,
and it is unclear whether metabolic components may have altered since conception.
Generalisability
Around 90% of the study participants were white; thus our results are likely generalisable to
populations of pregnant women who are white and considered to be at low risk for disease.
The results may have limited applicability to other ethnic groups with potentially different pat-
terns of metabolic health and known differences in risk for pregnancy complications. It is also
unclear whether these results are generalisable to women of all parities. However, women who
have had a complication in a previous pregnancy may modify their behaviours, and clinicians
would monitor them more closely in subsequent pregnancies.
Conclusion
We did not compare the impact of individual metabolic components with that of MetS as a
composite, and therefore cannot conclude that MetS is better at identifying women at risk.
However, more than half of the women who had MetS in early pregnancy developed a preg-
nancy complication compared with just over a third of women who did not have MetS. Fur-
thermore, while increasing BMI increases the probability of GDM, the addition of MetS
exacerbates this probability. Further studies are required to determine if individual MetS com-
ponents act synergistically or independently. It is currently unclear whether women in this
study had an adverse metabolic profile prior to pregnancy, and, therefore, studies to assess and
monitor changes in metabolic profile pre-conception and throughout pregnancy may be help-
ful. Young women identified as having poor metabolic health in pregnancy are at increased
risk for pregnancy complications, and these women will likely need metabolic follow-up in the
years after their pregnancy.
Supporting information
S1 STROBE Checklist. STROBE checklist.
(DOCX)
S1 Fig. Study flow chart. �Groups not mutually exclusive (total n = 98 with missing measure-
ments).
(TIF)
S2 Fig. Box plots demonstrating median (interquartile range) for each MetS component,
according to MetS status. Dotted line represents cut-point for IDF definition for MetS com-
ponents: reduced HDL-C (<1.29 mmol/l [<50 mg/dl]), raised TGs (�1.70 mmol/l [�150 mg/
dl]), raised plasma glucose (�5.6 mmol/l), raised systolic BP (�130 mm Hg) or raised diastolic
BP (�85 mm Hg), and high WC (�80 cm).
(TIF)
Metabolic syndrome and pregnancy complications
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002710 December 4, 2018 12 / 16
S3 Fig. UpSet plot displaying the frequency for each combination of MetS components.
(TIFF)
S4 Fig. UpSet plot displaying the frequency for each combination of MetS components in
women with BMI <30 kg/m2.
(TIFF)
S5 Fig. UpSet plot displaying the frequency for each combination of MetS components in
women with BMI�30 kg/m2.
(TIFF)
S1 Table. Missing data summary.
(XLSX)
S2 Table. Number and percentage of women with metabolic abnormalities, according to
MetS status.
(XLSX)
S3 Table. Crude numbers and percentages of women with each pregnancy complication, in
women with and without MetS.
(XLSX)
S1 Text. Study protocol and analysis plan.
(DOC)
Acknowledgments
The authors wish to thank all of the SCOPE participants and the SCOPE research midwives in
each centre, Robyn North for her contributions in establishing the SCOPE study, and Eliza
Chan for her role in establishing the database. They also thank MedSciNet for provision and
maintenance of the database.
Author Contributions
Conceptualization: Lucilla Poston, Lesley M. McCowan, Louise C. Kenny, Jenny E. Myers,
James J. Walker, Gus A. Dekker, Claire T. Roberts.
Data curation: Lucilla Poston, Lesley M. McCowan, Louise C. Kenny, Jenny E. Myers, James
J. Walker, Gus A. Dekker, Claire T. Roberts.
Formal analysis: Luke E. Grzeskowiak, Shalem Y. Leemaqz.
Funding acquisition: Lucilla Poston, Lesley M. McCowan, Louise C. Kenny, Jenny E. Myers,
James J. Walker, Gus A. Dekker, Claire T. Roberts.
Methodology: Jessica A. Grieger, Tina Bianco-Miotto, Luke E. Grzeskowiak, Claire T.
Roberts.
Writing – original draft: Jessica A. Grieger.
Writing – review & editing: Tina Bianco-Miotto, Luke E. Grzeskowiak, Shalem Y. Leemaqz,
Lucilla Poston, Lesley M. McCowan, Louise C. Kenny, Jenny E. Myers, James J. Walker,
Gus A. Dekker, Claire T. Roberts.
References
1. Knight-Agarwal CR, Williams LT, Davis D, Davey R, Cochrane T, Zhang H, et al. Association of BMI
and interpregnancy BMI change with birth outcomes in an Australian obstetric population: a
Metabolic syndrome and pregnancy complications
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002710 December 4, 2018 13 / 16
retrospective cohort study. BMJ Open. 2016; 6:e010667. https://doi.org/10.1136/bmjopen-2015-
010667 PMID: 27165646
2. Leddy MA, Power ML, Schulkin J. The impact of maternal obesity on maternal and fetal health. Rev
Obstet Gynecol. 2008; 1:170–8. PMID: 19173021
3. Scott-Pillai R, Spence D, Cardwell CR, Hunter A, Holmes VA. The impact of body mass index on mater-
nal and neonatal outcomes: a retrospective study in a UK obstetric population, 2004–2011. BJOG.
2013; 120:932–9. https://doi.org/10.1111/1471-0528.12193 PMID: 23530609
4. Shin D, Song WO. Prepregnancy body mass index is an independent risk factor for gestational hyperten-
sion, gestational diabetes, preterm labor, and small- and large-for-gestational-age infants. J Matern Fetal
Neonatal Med. 2015; 28:1679–86. https://doi.org/10.3109/14767058.2014.964675 PMID: 25211384
5. Anderson NH, Sadler LC, Stewart AW, Fyfe EM, McCowan LM. Independent risk factors for infants who
are small for gestational age by customised birthweight centiles in a multi-ethnic New Zealand popula-
tion. Aust N Z J Obstet Gynaecol. 2013; 53:136–42. https://doi.org/10.1111/ajo.12016 PMID: 23130970
6. Heindel JJ, Balbus J, Birnbaum L, Brune-Drisse MN, Grandjean P, Gray K, et al. Developmental origins
of health and disease: integrating environmental influences. Endocrinology. 2015; 156:3416–21.
https://doi.org/10.1210/EN.2015-1394 PMID: 26241070
7. Lee KK, Raja EA, Lee AJ, Bhattacharya S, Bhattacharya S, Norman JE, et al. Maternal obesity during
pregnancy associates with premature mortality and major cardiovascular events in later life. Hyperten-
sion. 2015; 66:938–44. https://doi.org/10.1161/HYPERTENSIONAHA.115.05920 PMID: 26370890
8. Chappell LC, Seed PT, Myers J, Taylor RS, Kenny LC, Dekker GA, et al. Exploration and confirmation
of factors associated with uncomplicated pregnancy in nulliparous women: prospective cohort study.
BMJ. 2013; 347:f6398. https://doi.org/10.1136/bmj.f6398 PMID: 24270055
9. Kearns K DA, Fitzgerald AP, Doherty E, Perry IJ. Chronic disease burden associated with overweight
and obesity in Ireland: the effects of a small BMI reduction at population level. BMC Public Health. 2014;
14:143. https://doi.org/10.1186/1471-2458-14-143 PMID: 24512151
10. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev
Endocr Metab Disord. 2013; 14:219–27. https://doi.org/10.1007/s11154-013-9252-x PMID: 23928851
11. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the meta-
bolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epide-
miology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and International Association for the Study of
Obesity. Circulation. 2009; 120:1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
PMID: 19805654
12. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome.
Brussels: International Diabetes Foundation; 2006 [cited 2018 Nov 7]. Available from: https://www.idf.
org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.
html.
13. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European
Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16:442–3. PMID: 10342346
14. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Hearth Association, et al.
Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American
Heart Association conference on scientific issues related to definition. Circulation. 2004; 109:433–8.
https://doi.org/10.1161/01.CIR.0000111245.75752.C6 PMID: 14744958
15. Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality
on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;
168:4761–8. https://doi.org/10.1016/j.ijcard.2013.07.230 PMID: 23972953
16. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resis-
tance and cancer. Proc Nutr Soc. 2012; 71:181–9. https://doi.org/10.1017/S002966511100320X PMID:
22051112
17. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Dia-
betes Care. 2008; 31:1898–904. https://doi.org/10.2337/dc08-0423 PMID: 18591398
18. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and
chronic kidney disease in U.S. adults. Ann Intern Med. 2004; 140:167–74. PMID: 14757614
19. Roberts CT. IFPA Award in Placentology Lecture: complicated interactions between genes and the
environment in placentation, pregnancy outcome and long term health. Placenta. 2010; 31(Suppl):S47–
53.
20. Wiznitzer A, Mayer A, Novack V, Sheiner E, Gilutz H, Malhotra A, et al. Association of lipid levels during
gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet
Gynecol. 2009; 201:482.e1–8.
Metabolic syndrome and pregnancy complications
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002710 December 4, 2018 14 / 16
21. Stekkinger E, Scholten R, van der Vlugt MJ, van Dijk AP, Janssen MC, Spaanderman ME. Metabolic
syndrome and the risk for recurrent pre-eclampsia: a retrospective cohort study. BJOG. 2013; 120:979–
86. https://doi.org/10.1111/1471-0528.12189 PMID: 23464593
22. Stekkinger E, Scholten RR, Heidema WM, Spaanderman ME. Recurrent pre-eclampsia in women with
metabolic syndrome and low plasma volume: a retrospective cohort study. BJOG. 2015; 122:1773–80.
https://doi.org/10.1111/1471-0528.13737 PMID: 26589850
23. Lei Q, Niu J, Lv L, Duan D, Wen J, Lin X, et al. Clustering of metabolic risk factors and adverse preg-
nancy outcomes: a prospective cohort study. Diabetes Metab Res Rev. 2016; 32:835–42. https://doi.
org/10.1002/dmrr.2803 PMID: 27037671
24. Moayeri M, Heida KY, Franx A, Spiering W, de Laat MW, Oudijk MA. Maternal lipid profile and the rela-
tion with spontaneous preterm delivery: a systematic review. Arch Gynecol Obstet. 2017; 295:313–23.
https://doi.org/10.1007/s00404-016-4216-5 PMID: 27807624
25. Ryckman KK, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy
and gestational diabetes: a systematic review and meta-analysis. BJOG. 2015; 122:643–51. https://doi.
org/10.1111/1471-0528.13261 PMID: 25612005
26. Varner MW, Rice MM, Landon MB, Casey BM, Reddy UM, Wapner RJ, et al. Pregnancies after the
diagnosis of mild gestational diabetes mellitus and risk of cardiometabolic disorders. Obstet Gynecol.
2017; 129:273–80. https://doi.org/10.1097/AOG.0000000000001863 PMID: 28079773
27. Lewandowski AJ, Leeson P. Preeclampsia, prematurity and cardiovascular health in adult life. Early
Hum Dev. 2014; 90:725–9. https://doi.org/10.1016/j.earlhumdev.2014.08.012 PMID: 25209092
28. Barrett HL, Dekker Nitert M, McIntyre HD, Callaway LK. Normalizing metabolism in diabetic pregnancy:
is it time to target lipids? Diabetes Care. 2014; 37:1484–93. https://doi.org/10.2337/dc13-1934 PMID:
24757231
29. Chatzi L, Plana E, Daraki V, Karakosta P, Alegkakis D, Tsatsanis C, et al. Metabolic syndrome in early
pregnancy and risk of preterm birth. Am J Epidemiol. 2009; 170:829–36. https://doi.org/10.1093/aje/
kwp211 PMID: 19713286
30. Davis P, McLeod K, Ransom M, Ongley P. The New Zealand socio-economic index of occupational sta-
tus (NZSEI). Research report # 2. Wellington: Statistics New Zealand; 1997 [cited 2018 Nov 12]. Avail-
able from: http://unpan1.un.org/intradoc/groups/public/documents/apcity/unpan011122.pdf.
31. Fyfe EM, Rivers KS, Thompson JM, Thiyagarajan KP, Groom KM, Dekker GA, et al. Elevated maternal
lipids in early pregnancy are not associated with risk of intrapartum caesarean in overweight and obese
nulliparous women. BMC Pregnancy Childbirth. 2013; 13:143. https://doi.org/10.1186/1471-2393-13-
143 PMID: 23835080
32. Kenny LC, Lavender T, McNamee R, O’Neill SM, Mills T, Khashan AS. Advanced maternal age and
adverse pregnancy outcome: evidence from a large contemporary cohort. PLoS ONE. 2013; 8(2):
e56583. https://doi.org/10.1371/journal.pone.0056583 PMID: 23437176
33. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for
pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ.
2011; 342:d1875. https://doi.org/10.1136/bmj.d1875 PMID: 21474517
34. Meek CL, Murphy HR, Simmons D. Random plasma glucose in early pregnancy is a better predictor of
gestational diabetes diagnosis than maternal obesity. Diabetologia. 2016; 59:445–52. https://doi.org/
10.1007/s00125-015-3811-5 PMID: 26589686
35. Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, et al. The detection, investigation and
management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol.
2000; 40:139–55. PMID: 10925900
36. World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in
pregnancy. WHO/NMH/MND/13.2. Geneva: World Health Organization; 2013 [cited 2018 Nov 7].
Available from: http://apps.who.int/iris/bitstream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf.
37. McCowan L, Stewart AW, Francis A, Gardosi J. A customised birthweight centile calculator developed
for a New Zealand population. Aust N Z J Obstet Gynaecol. 2004; 44:428–31. https://doi.org/10.1111/j.
1479-828X.2004.00272.x PMID: 15387864
38. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am
J Epidemiol. 1974; 99:325–32. PMID: 4825599
39. Rigby RA, Stasinopouos DM. Generalized additive models for location, scale and shape. J R Stat Soc
Ser C Appl Stat. 2005; 54:507–54.
40. Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, et al. Maternal obesity and risk of ges-
tational diabetes mellitus. Diabetes Care. 2007; 30:2070–6. https://doi.org/10.2337/dc06-2559a PMID:
17416786
Metabolic syndrome and pregnancy complications
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002710 December 4, 2018 15 / 16
41. Rahman MM, Abe SK, Kanda M, Narita S, Rahman MS, Bilano V, et al. Maternal body mass index and
risk of birth and maternal health outcomes in low- and middle-income countries: a systematic review
and meta-analysis. Obes Rev. 2015; 16:758–70. https://doi.org/10.1111/obr.12293 PMID: 26094567
42. Spradley FT, Palei AC, Granger JP. Increased risk for the development of preeclampsia in obese preg-
nancies: weighing in on the mechanisms. Am J Physiol Regul Integr Comp Physiol. 2015; 309:R1326–
43. https://doi.org/10.1152/ajpregu.00178.2015 PMID: 26447211
43. Grieger JA, Clifton VL. A review of the impact of dietary intakes in human pregnancy on infant birth-
weight. Nutrients. 2015; 7:153–78.
44. Hedderson MM, Ferrara A. High blood pressure before and during early pregnancy is associated with
an increased risk of gestational diabetes mellitus. Diabetes Care. 2008; 31:2362–7. https://doi.org/10.
2337/dc08-1193 PMID: 18809624
45. White SL, Pasupathy D, Sattar N, Nelson SM, Lawlor DA, Briley AL, et al. Metabolic profiling of gesta-
tional diabetes in obese women during pregnancy. Diabetologia. 2017; 60:1903–12. https://doi.org/10.
1007/s00125-017-4380-6 PMID: 28766127
46. Harville EW, Juonala M, Viikari JS, Raitakari OT. Preconception metabolic indicators predict gestational
diabetes and offspring birthweight. Gynecol Endocrinol. 2014; 30:840–4. https://doi.org/10.3109/
09513590.2014.937336 PMID: 25007009
47. Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah AN, Moron AF, et al. Prepregnancy BMI and
the risk of gestational diabetes: a systematic review of the literature with meta-analysis. Obes Rev.
2009; 10:194–203. https://doi.org/10.1111/j.1467-789X.2008.00541.x PMID: 19055539
48. White SL, Lawlor DA, Briley AL, Godfrey KM, Nelson SM, Oteng-Ntim E, et al. Early antenatal prediction
of gestational diabetes in obese women: development of prediction tools for targeted intervention. PLoS
ONE. 2016; 11(12):e0167846. https://doi.org/10.1371/journal.pone.0167846 PMID: 27930697
49. Forbes S, Barr SM, Reynolds RM, Semple S, Gray C, Andrew R, et al. Convergence in insulin resis-
tance between very severely obese and lean women at the end of pregnancy. Diabetologia. 2015;
58:2615–26. https://doi.org/10.1007/s00125-015-3708-3 PMID: 26248646
50. Wang Y, Zhao X, Zhao H, Ding H, Tan J, Chen J, et al. Risks for gestational diabetes mellitus and preg-
nancy-induced hypertension are increased in polycystic ovary syndrome. Biomed Res Int. 2013;
2013:182582. https://doi.org/10.1155/2013/182582 PMID: 24371816
51. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376:631–44.
https://doi.org/10.1016/S0140-6736(10)60279-6 PMID: 20598363
52. Andraweera PH DG, Arstall M, Bianco-Miotto T, Roberts CT. Complications of pregnancy and future
cardiovascular risk. In: Sawyer DB, Vasan RS, editors. Encyclopedia of cardiovascular research and
medicine. 1st edition. Oxford: Elsevier; 2017.
53. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table
for clinicians. Obstet Gynecol. 2009; 114:1326–31. https://doi.org/10.1097/AOG.0b013e3181c2bde8
PMID: 19935037
54. Lorentzen B, Endresen MJ, Clausen T, Henriksen T. Fasting serum free fatty acids and triglycerides are
increased before 20 weeks of gestation in women who later develop preeclampsia. Hypertens Preg-
nancy. 1994; 13:103–9.
55. van den Elzen HJ, Wladimiroff JW, Cohen-Overbeek TE, de Bruijn AJ, Grobbee DE. Serum lipids in
early pregnancy and risk of pre-eclampsia. Br J Obstet Gynaecol. 1996; 103:117–22. PMID: 8616126
56. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk
of preeclampsia: a meta-analysis. Am J Epidemiol. 2014; 180:346–58. https://doi.org/10.1093/aje/
kwu145 PMID: 24989239
57. Enquobahrie DA, Williams MA, Butler CL, Frederick IO, Miller RS, Luthy DA. Maternal plasma lipid con-
centrations in early pregnancy and risk of preeclampsia. Am J Hypertens. 2004; 17:574–81. https://doi.
org/10.1016/j.amjhyper.2004.03.666 PMID: 15233976
58. Clausen T, Djurovic S, Henriksen T. Dyslipidemia in early second trimester is mainly a feature of
women with early onset pre-eclampsia. BJOG. 2001; 108:1081–7. PMID: 11702841
59. Jin WY, Lin SL, Hou RL, Chen XY, Han T, Jin Y, et al. Associations between maternal lipid profile and
pregnancy complications and perinatal outcomes: a population-based study from China. BMC Preg-
nancy Childbirth. 2016; 16:60. https://doi.org/10.1186/s12884-016-0852-9 PMID: 27000102
60. Savvidou M, Nelson SM, Makgoba M, Messow CM, Sattar N, Nicolaides K. First-trimester prediction of
gestational diabetes mellitus: examining the potential of combining maternal characteristics and labora-
tory measures. Diabetes. 2010; 59:3017–22. https://doi.org/10.2337/db10-0688 PMID: 20876721
61. Nolan CJ, Riley SF, Sheedy MT, Walstab JE, Beischer NA. Maternal serum triglyceride, glucose toler-
ance, and neonatal birth weight ratio in pregnancy. Diabetes Care. 1995; 18:1550–6. PMID: 8722050
Metabolic syndrome and pregnancy complications
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002710 December 4, 2018 16 / 16
